Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies
Author:
Affiliation:
1. Department of Pulmonary MedicineShanghai Chest Hospital, Shanghai Jiao Tong University Shanghai China
2. Department of Emergency MedicineShanghai Chest Hospital, Shanghai Jiao Tong University Shanghai China
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32717
Reference37 articles.
1. Cancer statistics, 2017
2. The blockade of immune checkpoints in cancer immunotherapy
3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors;JCO Oncology Practice;2024-08-22
2. Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis;Gynecologic Oncology;2024-08
3. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant;Pathology;2024-06
4. Efficacy and Safety of Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People’s Republic of China: a Systematic Review and Meta-Analysis;JTO Clinical and Research Reports;2024-06
5. The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis;Cancer Immunology, Immunotherapy;2024-05-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3